Abstracts tagged "macrophages"

Abstract Number: 0940 • ACR Convergence 2023
A Novel Therapeutic Opportunity in Systemic Sclerosis: The Fibrolytic Activities of a Specialized Macrophage Secretome
Françis Bonnefoy¹, Susanne Behlke² and Sylvain Perruche¹, ¹Univ. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, RIGHT Institute/MedINNPharma, Besançon, France, ²MedINNPharma, Besançon, France
Background/Purpose: Systemic sclerosis (SSc) a complex and rare immune-mediated connective tissue disorder characterized by microvascular damage, inflammatory cell infiltration, and excessive deposition of extracellular matrix…
Abstract Number: 0048 • ACR Convergence 2023
Monosodium Urate Crystals Activate an Immune Tolerance Program That Restrains the Activation of Inflammatory Signaling in Macrophages During Gout Flares
Mohnish Alishala¹, Stephen Calderon¹, Anyan Chen¹, Monica Guma², Christopher glass¹ and Isidoro Cobo¹, ¹University of California San Diego, San Diego, CA, ²University of California San Diego, La Jolla, CA
Background/Purpose: Gout is the most frequent form of inflammatory arthritis, with episodes of self-resolving acute inflammation in the joint caused by the deposition of monosodium…
Abstract Number: 0944 • ACR Convergence 2023
Macrophages Regulate Adipocyte Differentiation and Proliferation in Skin Fibrosis
Chanhyuk Park, Helen Jarnagin, Michael Whitfield and Patricia Pioli, Geisel School of Medicine at Dartmouth, Hanover, NH
Background/Purpose: Autoimmune systemic sclerosis (SSc) is characterized by inflammation, vasculopathy, and dermal and internal organ fibrosis. A widely-reported but poorly understood aspect of SSc skin…
Abstract Number: 0051 • ACR Convergence 2023
CD14+CD64+ Classical Monocytes Are the Main Producers of IL-23 at the Enthesis
Nicole McDermott¹, Thomas Macleod¹, Ala Altaie¹, Liz Straszynski², Robert Dunsmuir³, Vishal Borse³, Peter Loughenbury³, Davide Simone⁴, Stevephen Sansom⁴, Christopher Buckley⁴ and Dennis McGonagle⁵, ¹University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom, ²Leeds Institute of Medical Research at St. James’s, Leeds, United Kingdom, ³Leeds Teaching Hospital NHS Trust, Leeds, United Kingdom, ⁴Kennedy Institute of Rheumatology, Oxford, United Kingdom, ⁵Leeds Biomedical Research Centre, University of Leeds, Leeds, United Kingdom
Background/Purpose: IL-23 is a key cytokine involved in diseases such as psoriasis, psoriatic arthritis and spondyloarthropathies (SpA) and inflammatory bowel disease.IL-23 is produced by activated…
Abstract Number: 0947 • ACR Convergence 2023
Fcγ Receptors Define Pro-Phagocytic Macrophages and Trigger Pro-Inflammatory Responses in Patients with Systemic Sclerosis
Amela Hukara¹, Gino Andrea Bonazza¹, Tracy Tabib², Raphael Micheroli¹, Suzana Jordan³, Kristina Bürki¹, Sylvie Schlitz Schönbächler¹, Adrian Ciurea⁴, Oliver Distler³, Robert Lafyatis⁵, Przemyslaw Blyszczuk¹ and Gabriela Kania¹, ¹Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ²Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, ³Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ⁴University Hospital Zurich, Zürich, Switzerland, ⁵University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Fcy receptors (FcγR) are opsonic phagocytic receptors, requiring tight regulations to prevent uncontrolled activation of pro-inflammatory phagocytosis. SSc macrophages display an alternatively-activated profibrotic phenotype.…
Abstract Number: 0053 • ACR Convergence 2023
Nintedanib Downregulates the Profibrotic M2 Phenotype of Macrophages Obtained from Systemic Sclerosis Patients Affected by Interstitial Lung Disease
Stefano Soldano¹, Paola Montagna¹, Emanuele Gotelli¹, Andrea Cere¹, Rosanna Campitiello¹, Sabrina Paolino¹, Carmen Pizzorni¹, Alberto Sulli¹, Vanessa Smith² and Maurizio Cutolo³, ¹Laboratory of Experimental Rheumatology and Academic Division of Rheumatology, Department of Internal Medicine, University of Genoa, IRCCS San Martino Polyclinic Hospital, Genoa, Italy, ²Ghent University Hospital, Gent, Belgium, ³Laboratory of Experimental Rheumatology, Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS San Martino Polyclinic, Genova, Italy
Background/Purpose: Systemic sclerosis (SSc) is a systemic autoimmune connective tissue disease, characterized by microvascular damage, alteration of immune response and progressive fibrosis of skin and…
Abstract Number: 0959 • ACR Convergence 2023
Redirecting Macrophage Immunophenotype Attenuates Inflammation and Fibrotic Activation in Systemic Sclerosis
Heetaek Yang¹, Rajan Bhandari¹, Saemi Han², Chanhyuk Park¹, Chen-Yu Wang², Emily Morris¹, Michael Whitfield¹ and Patricia Pioli¹, ¹Geisel School of Medicine at Dartmouth, Hanover, NH, ²Dartmouth College, Hanover, NH
Background/Purpose: Systemic Sclerosis (SSc) is a rare autoimmune disease with multiple clinical and pathological manifestations including vascular involvement, immune activation, oxidative stress, and fibrosis. In…
Abstract Number: 0057 • ACR Convergence 2023
GM-CSF receptor/SYK/JNK/FOXO1/CD11c Signaling Enhances Cell Migration to Promote Atherosclerosis
Daisuke Tsukui¹, Kimura Yoshitaka¹ and Hajime Kono², ¹Teikyo University School of Medicine, Itabashi-ku, Japan, ²Teikyo University School of Medicine, Tokyo, Japan
Background/Purpose: Atherosclerosis involves both dyslipidemia and chronic inflammatory disease; however, lipid-lowering agents do not completely eliminate the risks of cardiovascular events. In addition, chronic systemic…
Abstract Number: 1589 • ACR Convergence 2023
Epigenetic Regulation of DNMT3A by TFEB and DOT1L Through AMPK Signalling Orchestrates the Lysosomal Response of Macrophages During Gout and Clonal Hematopoiesis
Isidoro Cobo¹, Jessica Murillo-Saich², Mohnish Alishala¹, Stephen Calderon¹, Roxana Coras³, Nathanael Spann¹, Anyan Cheng⁴, Thomas Prohaska¹, Babak Razani⁵, Robert Terkeltaub¹, Benjamin Ebert⁶, Ru Liu Bryan⁷, Monica Guma⁸ and Christopher glass¹, ¹University of California San Diego, San Diego, CA, ²Department of Medicine, University of California San Diego, La Jolla, CA, ³Cedars-Sinai Medical Center, Los Angeles, CA, ⁴University of California San Diego, San Francisco, CA, ⁵Universit of Pittsburgh, Pittsburgh, PA, ⁶Dana-Farber Cancer Institute, Boston, MA, ⁷UCSD and VASDHS, San Diego, CA, ⁸San Diego VA Healthcare Service, La Jolla, CA
Background/Purpose: Gout is the most common form of inflammatory arthritis worldwide, which is characterised by the deposition of monosodium urate crystals (MSUc) in the joints…
Abstract Number: 0058 • ACR Convergence 2023
Macrophage Extracellular Traps Induced by Monosodium Urate or Calcium Pyrophosphate Crystals Form Independently of NLRP3 Inflammasome Activation
Douglas Daoudlarian¹, André Tiaden², Stavros Giaglis³, Ulrich Walker⁴, Petr Broz⁵, Tobias Maningold⁶ and Diego Kyburz¹, ¹University Hospital Basel, Basel, Switzerland, ²Laboratory for Experimental Rheumatology, Department of Biomedicine, University of Basel, Basel, Switzerland, ³University of Basel/University Hospital of Basel, Basel, Switzerland, ⁴Basel University Hospital, Basel, Switzerland, ⁵University of Lausanne, Lausanne, Switzerland, ⁶Department of Rheumatology, University Hospital Bern (Inselspital), University Bern, Bern, Switzerland
Background/Purpose: Monosodium urate (MSU) and calcium pyrophosphate (CPP) crystals are potent inducers of inflammation by activation of the inflammasome in neutrophils phagocytosing the crystals and…
Abstract Number: 1679 • ACR Convergence 2023
Effects of Janus Kinase Inhibitor on TNF-a and IL-6-Induced Osteoclasts and RANKL-Induced Osteoclasts in Peripheral Blood Monocytes from Patients with Rheumatoid Arthritis
Kazuhiro Yokota¹, Yoshimi Aizaki², Takuma Tsuzuki Wada¹, Hiroshi Kajiyama¹, Yasuto Araki², Hiroaki Yazawa², Yuji Akiyama² and Toshihide Mimura¹, ¹Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Iruma-gun, Japan, ²Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Saitama, Japan
Background/Purpose: We have previously demonstrated that a combination of TNF-a and IL-6 induces mouse osteoclast-like cells with bone resorption activity both in vitro and in…
Abstract Number: 0063 • ACR Convergence 2023
Investigating Macrophage Repopulation in the Synovium
Jessica Maciuch¹, Yidan Wang², Slim Fourati¹, Harris Perlman¹ and Deborah Winter³, ¹Northwestern University, Chicago, IL, ²Northwestern University, Hanover Park, IL, ³Northwestern University, Skokie, IL
Background/Purpose: Rheumatoid Arthritis (RA) is an autoimmune disease characterized by chronic inflammation of the joints. Macrophages are a key mediator of pro-inflammatory signaling, contributing to…
Abstract Number: 1722 • ACR Convergence 2023
Fate-mapping of Synovial Monocytes and Macrophages
Yidan Wang¹, Carla Cuda¹, Deborah Winter² and Harris Perlman¹, ¹Northwestern University, Chicago, IL, ²Northwestern University, Skokie, IL
Background/Purpose: Synovial monocytes and macrophages are heterogenous populations. These populations play diverse roles in the development of arthritis in humans and mice. In recent years,…
Abstract Number: 0270 • ACR Convergence 2023
Exploring the Potential of Oral Administration of 5-aminolevulinic Acid/sodium Ferrous Citrate in Adult-onset Still’s Disease: Preclinical Study in Mice and Pilot Investigation in Humans to Assess Efficacy and Safety
Tomohiro Koga¹, Remi Sumiyoshi¹, Yoshika Tsuji¹, Ken Kodama², Kaori Furukawa¹, Yushiro Endo¹ and Atsushi Kawakami³, ¹Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University, Nagasaki, Japan, ²Neophama Japan, Tokyo, Japan, ³Nagasaki University, Nagasaki, Japan
Background/Purpose: The primary objective of this study is to elucidate the therapeutic potential of 5-aminolevulinic acid/sodium ferrous citrate (5-ALA/SFC) in ameliorating the pathological manifestations associated…
Abstract Number: 1748 • ACR Convergence 2023
Macrophage Extracellular Traps Require Peptidylarginine Deiminase 2 and 4 and Are a Source of Citrullinated Antigens Bound by Rheumatoid Arthritis Autoantibodies
S Janna Bashar, Caitlyn Holmes and Miriam Shelef, University of Wisconsin, Madison, WI
Background/Purpose: Anti-citrullinated protein antibodies (ACPAs) are a hallmark of rheumatoid arthritis, but the sources of citrullinated antigens as well as which peptidylarginine deiminases (PADs) are…

« Previous Page
1
…
3
4
5
6
7
…
12
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].